

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Yestar Healthcare Holdings Company Limited**

**巨星醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2393)**

### **INSIDE INFORMATION**

This announcement is made by Yestar Healthcare Holdings Company Limited (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) made by The Stock Exchange of Hong Kong Limited and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong) (the “**SFO**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby informs the shareholders of the Company (the “**Shareholders**”) and the potential investors that on 21 January 2025, the Board has received a letter (the “**Letter**”) from Mr. Fok Hei Yu and Mr. Chow Wai Shing Daniel of FTI Consulting (the “**Receivers**”), who have been appointed as the joint and several receivers of 267,890,000 ordinary shares of the Company (the “**Charged Shares**”) held by Mr. Hartono James (“**Mr. James**”), a non-executive director of the Company. The Charged Shares represent approximately 11.49% of the total issued shares of the Company as at the date of this announcement.

The Company’s current business and operation remain as usual. In this regard, the Board wishes to emphasize that the abovementioned receivership does not concern the Company itself or its assets.

The Company will update the shareholders and potential investors on material developments in relation to the abovementioned receivership if and when appropriate in compliance with the Listing Rules and the SFO.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company, and if they are in any doubt about their position, they should consult their professional adviser(s).**

By order of the Board  
**Yestar Healthcare Holdings Company Limited**  
**Liao Changxiang**  
*Executive Director and Chief Executive Officer*

Hong Kong, 21 January 2025

*As at the date of this announcement, the executive Directors are Ms. Liao Changxiang and Mr. Qiao Jinrong; the non-executive Director is Mr. Hartono James; and the independent non-executive Directors are Mr. Zeng Jinsong, Mr. Zhao Ziwei and Mr. Koeswondo Michael David.*